Review of nano technology of Covid 19 vaccines

Boyaka, P. N. (2017). "Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems." The Journal of Immunology 199(1): 9-16.

Bull, J. J., S. L. Nuismer and R. Antia (2019). "Recombinant vector vaccine evolution." PLoS computational biology 15(7): e1006857.

Campos, E. V., A. E. Pereira, J. L. De Oliveira, L. B. Carvalho, M. Guilger-Casagrande, R. De Lima and L. F. Fraceto (2020). "How can nanotechnology help to combat COVID-19? Opportunities and urgent need." Journal of Nanobiotechnology 18(1): 1-23.

Chauhan, G., M. J. Madou, S. Kalra, V. Chopra, D. Ghosh and S. O. Martinez-Chapa (2020). "Nanotechnology for COVID-19: therapeutics and vaccine research." ACS nano 14(7): 7760-7782.

Chen, W., U. Strych, P. Hotez and M. Bottazzi "March 2020." The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep https://doi. org/10.1007/s40475-020-00201-6.

Choi, Y. and J. Chang (2013). "Viral vectors for vaccine applications." Clinical and experimental vaccine research 2(2): 97.

Chung, Y. H., V. Beiss, S. N. Fiering and N. F. Steinmetz (2020). "COVID-19 vaccine frontrunners and their nanotechnology design." ACS nano 14(10): 12522-12537.

Echevarría-Zuno, S., J. M. Mejía-Aranguré, A. J. Mar-Obeso, C. Grajales-Muñiz, E. Robles-Pérez, M. González-León, M. C. Ortega-Alvarez, C. Gonzalez-Bonilla, R. A. Rascón-Pacheco and V. H. Borja-Aburto (2009). "Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis." The Lancet 374(9707): 2072-2079.

Flotte, T. (2004). "Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors." Gene therapy 11(10): 805-810.

Frey, S. E., P. L. Winokur, R. A. Salata, S. S. El-Kamary, C. B. Turley, E. B. Walter Jr, C. M. Hay, F. K. Newman, H. R. Hill and Y. Zhang (2013). "Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario." Vaccine 31(29): 3025-3033.

Jackson, L. A., E. J. Anderson, N. G. Rouphael, P. C. Roberts, M. Makhene, R. N. Coler, M. P. McCullough, J. D. Chappell, M. R. Denison and L. J. Stevens (2020). "An mRNA vaccine against SARS-CoV-2—preliminary report." New England Journal of Medicine.

Klein, S. L., A. Jedlicka and A. Pekosz (2010). "The Xs and Y of immune responses to viral vaccines." The Lancet infectious diseases 10(5): 338-349.

Li, H., N. Malani and S. Hamilton (2011). "Assessing the potential for AAV vector genotoxicity in a murine model. Blood. 2011; 117 (12): 3311-3319." Blood 117(24).

Park, K. S., X. Sun, M. E. Aikins and J. J. Moon (2020). "Non-viral COVID-19 vaccine delivery systems." Advanced drug delivery reviews.

Mulligan, M., K. Lyke, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, K. Neuzil, V. Raabe, R. Bailey and K. Swanson Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. medRxiv. 20202020.06. 30.20142570.

Park, K. S., X. Sun, M. E. Aikins and J. J. Moon (2020). "Non-viral COVID-19 vaccine delivery systems." Advanced drug delivery reviews.

Perrie, Y., F. Crofts, A. Devitt, H. R. Griffiths, E. Kastner and V. Nadella (2016). "Designing liposomal adjuvants for the next generation of vaccines." Advanced drug delivery reviews 99: 85-96.

Pene, F., A. Merlat, A. Vabret, F. Rozenberg, A. Buzyn, F. Dreyfus, A. Cariou, F. Freymuth and P. Lebon (2003). "Coronavirus 229E-related pneumonia in immunocompromised patients." Clinical infectious diseases 37(7): 929-932.

Rai, M., S. Bonde, A. Yadav, Y. Plekhanova, A. Reshetilov, I. Gupta, P. Golińska, R. Pandit and A. P. Ingle (2020). "Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints." Expert Review of Anti-infective Therapy: 1-10.

Richner, J. M., S. Himansu, K. A. Dowd, S. L. Butler, V. Salazar, J. M. Fox, J. G. Julander, W. W. Tang, S. Shresta and T. C. Pierson (2017). "Modified mRNA vaccines protect against Zika virus infection." Cell 168(6): 1114-1125. e1110.

Ruiz‐Hitzky, E., M. Darder, B. Wicklein, C. Ruiz‐Garcia, R. Martín‐Sampedro, G. Del Real and P. Aranda (2020). "Nanotechnology responses to COVID‐19." Advanced healthcare materials 9(19): 2000979.

Shin, M. D., S. Shukla, Y. H. Chung, V. Beiss, S. K. Chan, O. A. Ortega-Rivera, D. M. Wirth, A. Chen, M. Sack and J. K. Pokorski (2020). "COVID-19 vaccine development and a potential nanomaterial path forward." Nature nanotechnology 15(8): 646-655.

Sicot, G., G. Gourdon and M. Gomes-Pereira (2011). "Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges." Human Molecular Genetics 20(R2): R116-R123.

Thao, T. T. N., F. Labroussaa, N. Ebert, P. V’kovski, H. Stalder, J. Portmann, J. Kelly, S. Steiner, M. Holwerda and A. Kratzel (2020). "Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform." Nature 582(7813): 561-565.

Thomas, K. (2020). "US Will Pay $1.6 Billion to Novavax for Coronavirus Vaccine." New York Times.

Vartak, A. and S. J. Sucheck (2016). "Recent advances in subunit vaccine carriers." Vaccines 4(2): 12.

Weiss, C., M. Carriere, L. Fusco, I. Capua, J. A. Regla-Nava, M. Pasquali, J. A. Scott, F. Vitale, M. A. Unal and C. Mattevi (2020). "Toward nanotechnology-enabled approaches against the COVID-19 pandemic." ACS nano 14(6): 6383-6406.

Wrapp, D., N. Wang, K. S. Corbett, J. A. Goldsmith, C.-L. Hsieh, O. Abiona, B. S. Graham and J. S. McLellan (2020). "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation." Science 367(6483): 1260-1263

Yang, D. (2021). "Application of Nanotechnology in the COVID-19 Pandemic." International Journal of Nanomedicine 16: 623.

Zhang, Y., X. Geng, Y. Tan, Q. Li, C. Xu, J. Xu, L. Hao, Z. Zeng, X. Luo and F. Liu (2020). "New understanding of the damage of SARS-CoV-2 infection outside the respiratory system." Biomedicine & Pharmacotherapy: 110195.

Zhu, F.-C., Y.-H. Li, X.-H. Guan, L.-H. Hou, W.-J. Wang, J.-X. Li, S.-P. Wu, B.-S. Wang, Z. Wang and L. Wang (2020). "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial." The Lancet 395(10240): 1845-1854.